Anti-fibroblast activation protein antibodies and methods and uses thereof
AssigneeLudwig Institute for Cancer Research
InventorsChristoph Renner, Eliane Fischer, Stefan Bauer, Thomas Wüest
Life of this patent
Estimating the term…
Loading patent…
AssigneeLudwig Institute for Cancer Research
InventorsChristoph Renner, Eliane Fischer, Stefan Bauer, Thomas Wüest
Estimating the term…
Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.
An isolated antibody or fragment thereof which recognizes human and mouse FAP and does not react with CD26 (DPPIV) and comprises the heavy chain variable region CDR domain sequences as set out in SEQ ID NOs:
Dependencies are inferred from the claim text.